Header Logo

Connection

Idoroenyi Amanam to Humans

Back to Details
This is a "connection" page, showing publications Idoroenyi Amanam has written about Humans.
Idoroenyi Amanam
Connection Strength
1.331
Humans
  1. Myelofibrosis-associated extramedullary hematopoiesis: Insights into hepatic, pulmonary, and thrombotic complications. Blood Rev. 2026 Jan; 75:101355.
    View in: PubMed
    Score: 0.099
  2. Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies. Hematology Am Soc Hematol Educ Program. 2023 12 08; 2023(1):164-170.
    View in: PubMed
    Score: 0.086
  3. Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience. Cancer Med. 2023 05; 12(10):11248-11253.
    View in: PubMed
    Score: 0.083
  4. Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis. Leuk Lymphoma. 2022 12; 63(13):3268-3270.
    View in: PubMed
    Score: 0.079
  5. Immune thrombocytopenia after immune checkpoint inhibitor therapy. Br J Haematol. 2021 05; 193(3):677-681.
    View in: PubMed
    Score: 0.071
  6. Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis? JCO Oncol Pract. 2021 01; 17(1):52-53.
    View in: PubMed
    Score: 0.068
  7. The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 2018 Aug; 14(19):1897-1908.
    View in: PubMed
    Score: 0.058
  8. Perspectives in Head and Neck Medical Oncology. Cancer Treat Res. 2018; 174:163-185.
    View in: PubMed
    Score: 0.057
  9. Applications for oncologic drugs: a descriptive analysis of the oncologic drugs advisory committee reviews. Oncologist. 2014 Mar; 19(3):299-304.
    View in: PubMed
    Score: 0.044
  10. Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2026 Jul; 32(7):877.e1-877.e11.
    View in: PubMed
    Score: 0.025
  11. FLAG-Ida-Venetoclax vs CLIA-venetoclax for relapsed and refractory AML during a fludarabine shortage: A single center experience. J Oncol Pharm Pract. 2026 Apr; 32(3):555-559.
    View in: PubMed
    Score: 0.025
  12. Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis. Bone Marrow Transplant. 2026 01; 61(1):82-91.
    View in: PubMed
    Score: 0.025
  13. MicroRNA-142 improves IL1RAP CAR-T cell activity in acute myeloid leukemia. J Hematol Oncol. 2025 11 12; 18(1):99.
    View in: PubMed
    Score: 0.025
  14. Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment. Transplant Cell Ther. 2025 Oct; 31(10):824.e1-824.e13.
    View in: PubMed
    Score: 0.024
  15. Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease. Expert Opin Investig Drugs. 2025 May; 34(5):391-400.
    View in: PubMed
    Score: 0.024
  16. TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL. Blood Adv. 2025 May 13; 9(9):2159-2172.
    View in: PubMed
    Score: 0.024
  17. Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect. Bone Marrow Transplant. 2025 May; 60(5):625-631.
    View in: PubMed
    Score: 0.023
  18. Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis. Front Immunol. 2025; 16:1543099.
    View in: PubMed
    Score: 0.023
  19. Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease. Bone Marrow Transplant. 2025 02; 60(2):165-174.
    View in: PubMed
    Score: 0.023
  20. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood. 2024 Nov 07; 144(19):2033-2044.
    View in: PubMed
    Score: 0.023
  21. Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study. Int J Mol Sci. 2024 Sep 23; 25(18).
    View in: PubMed
    Score: 0.023
  22. Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation. Leuk Res. 2024 10; 145:107565.
    View in: PubMed
    Score: 0.023
  23. Hypomethylating Agents are Effective in Treatment for Relapsed Myelofibrosis After Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2024 11; 30(11):1091.e1-1091.e8.
    View in: PubMed
    Score: 0.023
  24. Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings. Bone Marrow Transplant. 2024 Nov; 59(11):1542-1551.
    View in: PubMed
    Score: 0.023
  25. IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells. J Hematol Oncol. 2024 08 14; 17(1):67.
    View in: PubMed
    Score: 0.023
  26. Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation. Transplant Cell Ther. 2024 10; 30(10):1013.e1-1013.e12.
    View in: PubMed
    Score: 0.023
  27. High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy. Leuk Lymphoma. 2024 07; 65(7):1020-1023.
    View in: PubMed
    Score: 0.022
  28. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Transplant Cell Ther. 2023 08; 29(8):515.e1-515.e7.
    View in: PubMed
    Score: 0.021
  29. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions. Am J Hematol. 2023 06; 98(6):848-856.
    View in: PubMed
    Score: 0.020
  30. Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study. Front Immunol. 2023; 14:1114131.
    View in: PubMed
    Score: 0.020
  31. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab. Transplant Cell Ther. 2023 05; 29(5):314-320.
    View in: PubMed
    Score: 0.020
  32. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). Leuk Lymphoma. 2022 12; 63(13):3232-3236.
    View in: PubMed
    Score: 0.020
  33. Adoptive transfer of functional SARS-COV-2-specific immunity from donor graft to hematopoietic stem cell transplant recipients. Am J Hematol. 2022 11; 97(11):E404-E407.
    View in: PubMed
    Score: 0.020
  34. Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. Bone Marrow Transplant. 2022 02; 57(2):232-242.
    View in: PubMed
    Score: 0.019
  35. Characteristics and Trends of Adult Acute Lymphoblastic Leukemia in a Large, Public Safety-Net Hospital. Clin Lymphoma Myeloma Leuk. 2020 06; 20(6):e320-e327.
    View in: PubMed
    Score: 0.017
  36. Precision medicine and actionable alterations in lung cancer: A single institution experience. PLoS One. 2020; 15(2):e0228188.
    View in: PubMed
    Score: 0.017
  37. Mutation and immune profiling of metaplastic breast cancer: Correlation with survival. PLoS One. 2019; 14(11):e0224726.
    View in: PubMed
    Score: 0.016
  38. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019 07 01; 30(7):1096-1103.
    View in: PubMed
    Score: 0.016
  39. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. Am J Clin Oncol. 2019 04; 42(4):337-344.
    View in: PubMed
    Score: 0.016
  40. Targeted Therapies in Non-small-Cell Lung Cancer. Cancer Treat Res. 2019; 178:3-43.
    View in: PubMed
    Score: 0.015
  41. Therapeutic antibodies: A new era in the treatment of respiratory diseases? Pharmacol Ther. 2018 09; 189:149-172.
    View in: PubMed
    Score: 0.015
  42. Current and future therapies for advanced pancreatic cancer. J Surg Oncol. 2017 Jul; 116(1):25-34.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.